181 related articles for article (PubMed ID: 15283683)
1. Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
Gunin AG; Bitter AD; Demakov AB; Vasilieva EN; Suslonova NV
J Endocrinol; 2004 Aug; 182(2):229-39. PubMed ID: 15283683
[TBL] [Abstract][Full Text] [Related]
2. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
Gunin AG; Kapitova IN; Suslonova NV
J Endocrinol; 2005 Jun; 185(3):539-49. PubMed ID: 15930180
[TBL] [Abstract][Full Text] [Related]
3. Effect of adrenocorticotrophic hormone on the development of oestrogen-induced changes and hyperplasia formation in the mouse uterus.
Gunin AG; Emelianov V; Tolmachev AS
Reproduction; 2002 Apr; 123(4):601-11. PubMed ID: 11914122
[TBL] [Abstract][Full Text] [Related]
4. Effect of prolactin and dopaminergic drugs on uterine response to chronic estrogen exposure.
Gunin AG; Emelianov V; Tolmachev AS; Tolmacheva A
J Endocrinol; 2002 Jan; 172(1):61-9. PubMed ID: 11786374
[TBL] [Abstract][Full Text] [Related]
5. Lithium treatment enhances estradiol-induced proliferation and hyperplasia formation in the uterus of mice.
Gunin AG; Emelianov VU; Mironkin IU; Morozov MP; Tolmachev AS
Eur J Obstet Gynecol Reprod Biol; 2004 May; 114(1):83-91. PubMed ID: 15099877
[TBL] [Abstract][Full Text] [Related]
6. Expression of estrogen receptor-alpha, glucocorticoid receptor, beta-catenin and glycogen synthase kinase-3beta in the uterus of mice following long-term treatment with estrogen and glucocorticoid hormones.
Gunin AG; Emelianov VU; Tolmachev AS
Eur J Obstet Gynecol Reprod Biol; 2003 Mar; 107(1):62-7. PubMed ID: 12593897
[TBL] [Abstract][Full Text] [Related]
7. Uterine response to estradiol under action of chorionic gonadotropin in mice.
Gunin AG; Emelianov VU; Mironkin IU; Morozov MP; Ivanov VA
Int J Gynecol Cancer; 2003; 13(4):485-96. PubMed ID: 12911726
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.
Desouza CV; Murthy SN; Diez J; Dunne B; Matta AS; Fonseca VA; McNamara DB
J Cardiovasc Pharmacol Ther; 2003 Dec; 8(4):297-305. PubMed ID: 14740079
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
10. Proliferation, mitosis orientation and morphogenetic changes in the uterus of mice following chronic treatment with both estrogen and glucocorticoid hormones.
Gunin AG; Mashin IN; Zakharov DA
J Endocrinol; 2001 Apr; 169(1):23-31. PubMed ID: 11250643
[TBL] [Abstract][Full Text] [Related]
11. Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Iglarz M; Touyz RM; Amiri F; Lavoie MF; Diep QN; Schiffrin EL
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):45-51. PubMed ID: 12524223
[TBL] [Abstract][Full Text] [Related]
12. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.
Srivastava RA
Atherosclerosis; 2011 Jan; 214(1):86-93. PubMed ID: 21093860
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the pharmacologic profile of a standardized soy extract in the ovariectomized rat model of menopause: effects on bone, uterus, and lipid profile.
Gallo D; Zannoni GF; Apollonio P; Martinelli E; Ferlini C; Passetti G; Riva A; Morazzoni P; Bombardelli E; Scambia G
Menopause; 2005; 12(5):589-600. PubMed ID: 16145313
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.
Egerod FL; Nielsen HS; Iversen L; Thorup I; Storgaard T; Oleksiewicz MB
Biomarkers; 2005; 10(4):295-309. PubMed ID: 16240504
[TBL] [Abstract][Full Text] [Related]
16. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
[TBL] [Abstract][Full Text] [Related]
17. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.
Smith SY; Samadfam R; Chouinard L; Awori M; Bénardeau A; Bauss F; Guldberg RE; Sebokova E; Wright MB
J Bone Miner Metab; 2015 Nov; 33(6):625-41. PubMed ID: 25534548
[TBL] [Abstract][Full Text] [Related]
18. Estrogen changes mitosis orientation in the uterine epithelia.
Gunin AG
Eur J Obstet Gynecol Reprod Biol; 2001 Jul; 97(1):85-9. PubMed ID: 11435016
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
Liang F; Wang F; Zhang S; Gardner DG
Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
[TBL] [Abstract][Full Text] [Related]
20. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Patel JJ; Butters OR; Arnett TR
Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
